Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation    DNDN   US24823Q1076

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Dendreon Corporation : StockCall Pre-Market Review on DNDN, SRPT, ACAD, CTIC, and MDVN

05/08/2013 | 08:00am US/Eastern
Recommend:
0

StockCall.com Provides Stock Research on Dendreon Corp., Sarepta Therapeutics Inc., ACADIA Pharmaceuticals Inc., Cell Therapeutics Inc., and Medivation Inc.

New York City, New York -- (May 08, 2013)

Biotechnology companies have been increasing competition from generic drug makers as patents on several blockbuster drugs continue to expire. In 2013 alone, patents on drugs with annual sales of nearly $30 billion are set to expire. For biotechnology companies, the key will be to boost their product pipelines in order to offset the loss from patent expirations. Biotechnology stocks ended on a mixed note on Tuesday even as the broad market rose to record high levels. Among the major movers yesterday were Dendreon Corporation (NASDAQ: DNDN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Cell Therapeutics Inc. (NASDAQ: CTIC), and Medivation Inc. (NASDAQ: MDVN). StockCall analysts initiated preliminary technical research on DNDN, SRPT, ACAD, CTIC, and MDVN. These free reports are accessible by signing today at

www.stockcall.com/register

Dendreon Corporation?s shares were among the major gainers in the biotechnology sector on Tuesday. The stock closed 1.51% higher at $4.70 on above average volume of 3.67 million. Despite yesterday?s gains, Dendreon?s shares are down more than 0.40% in the last three trading sessions. Year-to-date, the stock has fallen more than 11.10%. The biotech company?s shares are currently trading more than 61.50% below their 52-week high. The stock is currently trading below its 50-day and 200-day moving averages. The free technical analysis on DNDN is available by signing up at

www.StockCall.com/DNDN050813.pdf

Shares of Sarepta Therapeutics Inc. fell sharply in Tuesday?s trading session. The stock fell to an intraday low of $31.05 before finishing the day 2.04% lower at $31.22 on volume of 1 million. The company?s shares have fallen 4.20% in the last three sessions even as the broad market has rallied. The stock is currently trading below its 50-day moving average which is a bearish signal. Despite the recent losses, shares of the company have gained more than 21% so far this year as compared to a gain of 14% for the S&P 500. Register now to download the free research on SRPT at

www.StockCall.com/SRPT050813.pdf

Shares of ACADIA Pharmaceuticals Inc. slipped in trading on Tuesday, extending their losses from previous trading session. The stock fell to an intraday low of $11.80 before finishing the day 1.23% lower at $12.03 on volume of 1.94 million, taking its losses in the last three trading sessions to over 2.40%. ACADIA?s shares have been among the biggest gainers in the biotechnology sector so far in 2013, gaining more than 158.70%. In the last one month alone, the stock has jumped 50.75%. However, in the last few weeks the stock has traded sideways. Free report on ACAD can be accessed by registering at

www.StockCall.com/ACAD050813.pdf

Shares of Cell Therapeutics Inc. edged higher in yesterday?s trading session. The stock closed 0.85% higher at $1.19 on volume of 613,600, taking its gains in the last three sessions to over 1.70%. Cell Therapeutics? shares have fallen nearly 8.50% hitherto in 2013, underperforming the S&P 500. The stock is trading more than 82.30% below its 52-week high. Shares of CTIC, however, have recently crossed above their 50-day moving average which indicates that market sentiment has turned bullish.Register withStockCall and download the research on CTIC for free at

www.StockCall.com/CTIC050813.pdf

Shares of Medivation Inc. fell sharply in trading on Tuesday. The stock traded between $52.02 and $54 before finishing the day 2.05% lower at $52.13 on volume of 987,600. Medivation?s shares had an excellent run in April; however, the stock has seen a sharp pullback after failing to break through $55 resistance level. Shares of MDVN are still trading above their 50-day and 200-day moving averages. Read the full free research on MDVN by signing up to StockCall at

www.StockCall.com/MDVN050813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
Recommend :
0
React to this article
Latest news on DENDREON CORPORATION
2d ago DENDREON : Immune Responses Enhanced and Sustained When PROVENGE® sipuleucel-T i..
04/17 DENDREON : Releases Preliminary Data from Analysis of Phase II Stand Study
04/11 DENDREON : Immune Responses Enhanced and Sustained When PROVENGE® (sipuleucel-T)..
03/12 DENDREON : Announces Fourth Quarter and 2013 Year End Results
03/12 DENDREON : Announces Plans to Make PROVENGE® Commercially Available in Europe
03/10 Exclusive - Germany OKs Northwest Bio brain cancer drug, shares soar
03/07 DENDREON CORPORATION : DENDREON CORP FILES (8-K) Disclosing Change in Directors ..
03/06 DENDREON CORPORATION : Dendreon Reports Intent to Make Provenge Commercially Ava..
03/05 DENDREON CORPORATION : Patent Issued for Promiscuous HER-2/Neu CD4 T Cell Epitop..
03/04 DENDREON CORPORATION : Dendreon Corp. Assigned Patent
Advertisement
Chart
Duration : Period :
Dendreon Corporation Technical Analysis Chart | DNDN | US24823Q1076 | 4-Traders
Income Statement Evolution
Dendreon Corporation : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF